NASDAQ:VTYX Ventyx Biosciences (VTYX) Stock Forecast, Price & News $33.87 -0.66 (-1.91%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$33.59▼$34.6450-Day Range$29.80▼$37.7652-Week Range$23.89▼$47.25Volume369,031 shsAverage Volume507,798 shsMarket Capitalization$1.99 billionP/E RatioN/ADividend YieldN/APrice Target$57.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Ventyx Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside70.9% Upside$57.88 Price TargetShort InterestBearish20.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 5 Articles This WeekInsider TradingSelling Shares$17.78 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.26) to ($3.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector741st out of 961 stocksPharmaceutical Preparations Industry345th out of 454 stocks 3.5 Analyst's Opinion Consensus RatingVentyx Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $57.88, Ventyx Biosciences has a forecasted upside of 70.9% from its current price of $33.87.Amount of Analyst CoverageVentyx Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.71% of the float of Ventyx Biosciences has been sold short.Short Interest Ratio / Days to CoverVentyx Biosciences has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in Ventyx Biosciences has recently decreased by 1.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVentyx Biosciences does not currently pay a dividend.Dividend GrowthVentyx Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTYX. Previous Next 2.4 News and Social Media Coverage News SentimentVentyx Biosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Ventyx Biosciences this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Ventyx Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ventyx Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,778,968.00 in company stock.Percentage Held by Insiders24.39% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ventyx Biosciences are expected to decrease in the coming year, from ($3.26) to ($3.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ventyx Biosciences is -12.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ventyx Biosciences is -12.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVentyx Biosciences has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ventyx Biosciences (NASDAQ:VTYX) StockVentyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.Read More VTYX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTYX Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comVentyx Biosciences (NASDAQ:VTYX) Stock Price Down 2.5%September 24, 2023 | americanbankingnews.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Rating of "Buy" from AnalystsSeptember 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. September 22, 2023 | americanbankingnews.comSomu Subramaniam Sells 56,665 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) StockSeptember 11, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)September 11, 2023 | finance.yahoo.comInsider Sell: CFO Martin Auster Sells 26,472 Shares of Ventyx Biosciences IncAugust 20, 2023 | fool.comVentyx Biosciences (NASDAQ: VTYX)August 15, 2023 | finance.yahoo.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call TranscriptSeptember 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 14, 2023 | seekingalpha.comVentyx: Promising, But Data Will Need To Justify Optimistic ValuationAugust 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Amylyx Pharmaceuticals Inc (AMLX) and Aptose Biosciences (APTO)August 11, 2023 | markets.businessinsider.comWhere Ventyx Biosciences Stands With AnalystsAugust 11, 2023 | finanznachrichten.deVentyx Biosciences, Inc.: Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate ProgressAugust 11, 2023 | finance.yahoo.comVentyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate ProgressAugust 3, 2023 | finance.yahoo.comVentyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023August 2, 2023 | finance.yahoo.comVentyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceJuly 11, 2023 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)July 7, 2023 | seekingalpha.comWhy did Ventyx Biosciences stock drop today? Large shareholder saleJuly 7, 2023 | benzinga.comDirector of Ventyx Biosciences Makes $5.23M SaleJuly 7, 2023 | benzinga.com10% Owner of Ventyx Biosciences Sold $5.23M In StockJuly 6, 2023 | benzinga.comChief Executive Officer at Ventyx Biosciences Exercises Options Worth $1.08MJuly 6, 2023 | benzinga.comChief Business Officer at Ventyx Biosciences Exercises Options Worth $546KJuly 5, 2023 | markets.businessinsider.comAnalyst Ratings for Ventyx BiosciencesJuly 5, 2023 | markets.businessinsider.comLifeSci Capital Remains a Buy on Ventyx Biosciences (VTYX)July 5, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Ventyx Biosciences (VTYX), Avadel Pharmaceuticals (AVDL)July 3, 2023 | finance.yahoo.comWhy Shares of Ventyx Biosciences Rose MondayJune 15, 2023 | seekingalpha.comVentyx: Critical Proof Of Concept Data Later This YearSee More Headlines Receive VTYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address VTYX Company Calendar Last Earnings8/10/2023Today9/26/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTYX CUSIPN/A CIK1851194 Webwww.ventyxbio.com Phone760-593-4832FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Forecast$57.88 High Stock Price Forecast$77.00 Low Stock Price Forecast$46.00 Forecasted Upside/Downside+70.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.67% Return on Assets-41.01% Debt Debt-to-Equity RatioN/A Current Ratio17.31 Quick Ratio17.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.25 per share Price / Book5.42Miscellaneous Outstanding Shares58,710,000Free Float44,391,000Market Cap$1.99 billion OptionableNot Optionable Beta-0.36 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Sheila K. Gujrathi M.D. (Age 53)Exec. Chairperson Comp: $125kDr. Raju S. Mohan Ph.D. (Age 65)Founder, CEO & Director Comp: $989.99kDr. William J. Sandborn M.D. (Age 60)Ph.D., Pres & Chief Medical Officer Comp: $872.26kDr. John M. Nuss Ph.D. (Age 64)Chief Scientific Officer Comp: $656.99kDr. Martin Douglas Auster M.D. (Age 48)Chief Financial Officer Mr. Christopher W. Krueger J.D. (Age 55)MBA, Chief Bus. Officer More ExecutivesKey CompetitorsHarmony BiosciencesNASDAQ:HRMYGemini TherapeuticsNASDAQ:GMTXAmphastar PharmaceuticalsNASDAQ:AMPHSchrödingerNASDAQ:SDGRGalapagosNASDAQ:GLPGView All CompetitorsInsiders & InstitutionsBarclays PLCBought 5,954 shares on 9/21/2023Ownership: 0.040%Somu SubramaniamSold 56,665 sharesTotal: $2.14 M ($37.81/share)William J SandbornSold 11,900 sharesTotal: $400,316.00 ($33.64/share)Affinity Asset Advisors LLCSold 159,312 shares on 8/21/2023Ownership: 0.171%California State Teachers Retirement SystemBought 24,666 shares on 8/21/2023Ownership: 0.083%View All Insider TransactionsView All Institutional Transactions VTYX Stock - Frequently Asked Questions Should I buy or sell Ventyx Biosciences stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTYX shares. View VTYX analyst ratings or view top-rated stocks. What is Ventyx Biosciences' stock price forecast for 2023? 7 analysts have issued 1-year price objectives for Ventyx Biosciences' shares. Their VTYX share price forecasts range from $46.00 to $77.00. On average, they expect the company's share price to reach $57.88 in the next twelve months. This suggests a possible upside of 70.9% from the stock's current price. View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts. How have VTYX shares performed in 2023? Ventyx Biosciences' stock was trading at $32.79 at the beginning of the year. Since then, VTYX shares have increased by 3.3% and is now trading at $33.87. View the best growth stocks for 2023 here. When is Ventyx Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our VTYX earnings forecast. How were Ventyx Biosciences' earnings last quarter? Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its earnings results on Thursday, August, 10th. The company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.20. During the same quarter in the prior year, the company posted ($0.39) earnings per share. What ETFs hold Ventyx Biosciences' stock? ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL), Alger Mid Cap 40 ETF (FRTY), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares U.S. Pharmaceuticals ETF (IHE). When did Ventyx Biosciences IPO? (VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share. What is Ventyx Biosciences' stock symbol? Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX." Who are Ventyx Biosciences' major shareholders? Ventyx Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.99%), Capital International Investors (5.07%), Goldman Sachs Group Inc. (2.66%), Holocene Advisors LP (2.61%), State Street Corp (1.77%) and Driehaus Capital Management LLC (1.64%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White. View institutional ownership trends. How do I buy shares of Ventyx Biosciences? Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ventyx Biosciences' stock price today? One share of VTYX stock can currently be purchased for approximately $33.87. How much money does Ventyx Biosciences make? Ventyx Biosciences (NASDAQ:VTYX) has a market capitalization of $1.99 billion. The company earns $-108,430,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. How can I contact Ventyx Biosciences? The official website for the company is www.ventyxbio.com. The company can be reached via phone at 760-593-4832 or via email at ir@ventyxbio.com. This page (NASDAQ:VTYX) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.